A practical reference on mass spectrometry: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-10 and is reviewed periodically as new material appears.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
== In popular culture == The 1896 Gilbert and Sullivan operetta The Grand Duke features sausage rolls as a plot device, where conspirators recognise one another by eating sausage rolls. From 2018 to 2022, English YouTuber LadBaby had five consecutive Christmas number ones on the UK Singles Chart with cover versions of songs where the lyrics were rewritten to reference sausage rolls, including "I Love Sausage Rolls", "Don't Stop Me Eatin'", and "Sausage Rolls for Everyone".
Guillemin and Schally were awarded the Nobel Prize in Physiology and Medicine in 1977 for their contributions to understanding "the peptide hormone production of the brain". In 1952, Andor Szentivanyi, of the University of South Florida, and Geza Filipp wrote the world's first research paper showing how neural control of immunity takes place through the hypothalamus.
=== Other methods === A commercial source for the cyanide group is diethylaluminum cyanide Et2AlCN which can be prepared from triethylaluminium and HCN. It has been used in nucleophilic addition to ketones. For an example of its use see: Kuwajima Taxol total synthesis Cyanide ions facilitate the coupling of dibromides. Reaction of α,α′-dibromoadipic acid with sodium cyanide in ethanol yields the cyano cyclobutane: Aromatic nitriles can be prepared from base hydrolysis of trichloromethyl aryl ketimines (RC(CCl3)=NH) in the Houben-Fischer synthesis α-Amino acids form nitriles and carbon dioxide via various means of oxidative decarboxylation. Henry Drysdale Dakin discovered this oxidation in 1916. From aryl carboxylic acids (Letts nitrile synthesis) Carbocyanation enables addition of a nitrile group across a multiple bond to yield a further nitrile. Aryl nitriles can be added to alkynes under catalysis by bis(cyclooctadiene)nickel(0) and trimethylphosphine, affording α,β-unsaturated nitriles. Modification of the reaction conditions, for example by employing a different phosphane or adding a frustrated Lewis pair such as trimethylaluminum or triphenylborane, allows addition of non-aromatic nitriles, both saturated and α,β-unsaturated. Carbocyanation reactions that couple two molecules while introducing a nitrile group are also known, using hexabutyldistannane and tosyl cyanide as the cyanide source. Carboxylic acids can be converted to the corresponding nitriles by reaction with indium(III) chloride in acetonitrile at 200 °C.
== Safety and regulation == The European Food Safety Authority (EFSA) and the United States Food and Drug Administration (FDA) have evaluated TBHQ and determined that it is safe to consume at the concentration allowed in foods. The FDA and European Union both set an upper limit of 0.02% (200 mg/kg) of the oil or fat content in foods. It has not been approved in Japan, hence import of food containing TBHQ for selling is not allowed in Japan as of 2007. At very high doses, it has some negative health effects on lab animals, such as producing precursors to stomach tumors and damage to DNA. A number of studies have shown that prolonged exposure to very high doses of TBHQ may be carcinogenic, especially for stomach tumors. Other studies, however, have shown opposite effects, including inhibition against HCA-induced carcinogenesis (by depression of metabolic activation) for TBHQ and other phenolic antioxidants (TBHQ was one of several, and not the most potent) and reduction of nitrosamine-induced carcinogenesis (likely due to phase-II enzyme induction via Nrf2). The EFSA considers TBHQ to be noncarcinogenic. A 1986 review of scientific literature concerning the toxicity of TBHQ determined that a wide margin of safety exists between the levels of intake by humans and the doses that produce adverse effects in animal studies. In addition, TBHQ has been identified by high-throughput screening as having potential immunotoxic effects in 2021. It was previously reported in 2014 that TBHQ enhances allergy response in mice by promoting Th2 cells through Nrf2.
Sources: en.wikipedia.org
Refined sugar is made from raw sugar that has undergone a refining process to remove the molasses. Raw sugar is sucrose which is extracted from sugarcane or sugar beet. While raw sugar can be consumed, the refining process removes unwanted tastes and results in refined sugar or white sugar. The sugar may be transported in bulk to the country where it will be used and the refining process often takes place there. The first stage is known as affination and involves immersing the sugar crystals in a concentrated syrup that softens and removes the sticky brown coating without dissolving them. The crystals are then separated from the liquor and dissolved in water. The resulting syrup is treated either by a carbonatation or by a phosphatation process. Both involve the precipitation of a fine solid in the syrup and when this is filtered out, many of the impurities are removed at the same time. Removal of colour is achieved by using either a granular activated carbon or an ion-exchange resin. The sugar syrup is concentrated by boiling and then cooled and seeded with sugar crystals, causing the sugar to crystallise out. The liquor is spun off in a centrifuge and the white crystals are dried in hot air and ready to be packaged or used. The surplus liquor is made into refiners' molasses. The International Commission for Uniform Methods of Sugar Analysis sets standards for the measurement of the purity of refined sugar, known as ICUMSA numbers; lower numbers indicate a higher level of purity in the refined sugar. Refined sugar is widely used for industrial needs for higher quality.
24 June – David Hinton, the chief executive of South East Water, has blamed the increase in people working from home as a result of the COVID-19 pandemic for the implementation of a planned hosepipe ban on 26 June, with an estimated 20% increase in the use of drinking water in commuter towns. 25 June – Avon and Somerset Police confirm that a man in his 40s has died following a "medical incident" at the 2023 Glastonbury Festival. 26 June – An inquest opens into the death of Nicola Bulley. 27 June – The inquest into the death of Nicola Bulley returns a verdict of accidental death. Sarah Bentley resigns as chief executive of Thames Water after previously forgoing her bonus after raw sewage became a problem for the company. Nurses in England will not continue their strike action after a Royal College of Nursing ballot failed to garner enough votes to achieve a mandate. The majority of the 43% who voted favoured continued strike action, but this was below the 50% turnout required under trade union regulations. Senior consultants in England will begin strike action after 86% of those who took part in a ballot voted to take strike action; a previously announced 48-hour strike will now go ahead from 21 July. 28 June – The second Test match of the 2023 Ashes series is briefly interrupted when Just Stop Oil protestors invade the pitch at Lord's. Thames Water is reported to be in talks with the UK government to secure extra funding amid concerns the company is on the brink of collapse. 29 June – Sir John Mitting's interim report for the Undercover Policing Inquiry is published.
== Novel chiral selectors and CSPs == During the last couple of years there has been developments of CSPs based on novel chiral selectors viz. chitosan derivatives, cylofructan derivatives and chiral porous materials for HPLC chiral separation.
Sources: en.wikipedia.org
==== Bioactivation ==== As with all structurally-similar benzimidazole proton pump inhibitors, omeprazole is a prodrug. A basic molecule, it accumulates in the acidic canaliculi of parietal cells in a protonated form where the S=O group becomes S-OH, which in turn is interconvertible with an achiral, reactive sulfenamide form. The sulfenamide form is able to attach onto the cysteine residue on the H+/K+-ATPase, thereby irreversibly inhibiting it.
The mother of an 18-year-old who killed himself in 2021 sued anti-vaccine campaigner Gemma O'Doherty for misrepresenting and sensationalising his death in the freesheet, The Irish Light, last year to support conspiracy theory about the COVID-19 vaccine. 30 May – Ireland's 2022 census figures from the CSO show an older population, increased diversity, decreased religiosity, and a population surpassing five million for the first time since the great famine.
== Awards and honors == He was awarded the Louisa Gross Horwitz Prize from Columbia University in 1991, the Louis-Jeantet Prize for Medicine in 1993, the Otto Warburg Medal in 1999 and half of the Nobel Prize in Chemistry in 2002 for "his development of nuclear magnetic resonance spectroscopy for determining the three-dimensional structure of biological macromolecules in solution". He received the Bijvoet Medal of the Bijvoet Center for Biomolecular Research of Utrecht University in 2008. He was elected a Foreign Member of the Royal Society (ForMemRS) in 2010. In 2017 he was awarded the Endel Lippmaa Memorial Medal by the Estonian Academy of Sciences. He was also awarded the 2018 Fray International Sustainability Award at SIPS 2018 by FLOGEN Star Outreach.
It is thus crucial to identify the OSA for children with school difficulties; many cases remain unnoticed. Studies have shown that learning skills and behaviors can be improved if the OSA is treated, the neurocognitive and behavioral deficits are thus at least partly reversible. This reversible dimension has been postulated to be negatively correlated to the duration of the symptoms, which would mean that the longer the OSA is left untreated, the less reversible are the consequences.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.